ARS Pharmaceuticals Investment Thesis: A Needle-Free Disruptor with 60% Upside...
ARS Pharmaceuticals is set to reshape the $2.5 billion epinephrine market with its ground-breaking needle-free product, neffy. Following recent FDA approval, expansion plans are geared for global markets by 2027,...